The evolving cancer drugs fund

‘The evolution of the cancer drug appraisal process: hosted by BMJ, this promotional campaign article by Roche includes ‘How will it work?’, ‘Implications for breast cancer’, and ‘consequences for HER2+ breast cancer – coming soon’.

‘…A new model was introduced on 29th July 2016, through which NICE will evaluate new cancer drugs as well as those already funded through the CDF. However, the anticipated reforms to the NICE evaluation process have not taken place. NICE will use the original methodology employed in 2009, which resulted in the rejection of many cancer drugs – the reason the CDF was introduced in the first place.’


About bmitzi

Medical writer, author, artist. Cancer campaigner. Aiming always to improve health services and bring compassion into health care.
This entry was posted in Breast Cancer, Campaigns, cancer drugs, healthcare modernisation, patient safety and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s